Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Journal of Molecular Pathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-5261/2/2/17 |
| _version_ | 1797527955064225792 |
|---|---|
| author | Luigi Della Gravara Ciro Battiloro Antonietta Letizia Rosa Cantile Vito D'Agnano Giacomo Sica Danilo Rocco |
| author_facet | Luigi Della Gravara Ciro Battiloro Antonietta Letizia Rosa Cantile Vito D'Agnano Giacomo Sica Danilo Rocco |
| author_sort | Luigi Della Gravara |
| collection | DOAJ |
| description | Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing, impairing our capacity to personalize and guide treatment. Therefore, this paper aims to analyze the most promising emerging predictive biomarkers that could help us in the near future to select patients more effectively. |
| first_indexed | 2024-03-10T09:51:12Z |
| format | Article |
| id | doaj.art-cec325d03f124fe79e034abaacedddf0 |
| institution | Directory Open Access Journal |
| issn | 2673-5261 |
| language | English |
| last_indexed | 2024-03-10T09:51:12Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Molecular Pathology |
| spelling | doaj.art-cec325d03f124fe79e034abaacedddf02023-11-22T02:43:48ZengMDPI AGJournal of Molecular Pathology2673-52612021-06-012219720610.3390/jmp2020017Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy PatientsLuigi Della Gravara0Ciro Battiloro1Antonietta Letizia2Rosa Cantile3Vito D'Agnano4Giacomo Sica5Danilo Rocco6Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 81100 Naples, ItalyDepartment of Pulmonary Oncology, AORN dei Colli Monaldi, 80131 Naples, ItalyDepartment of Pulmonary Oncology, AORN dei Colli Monaldi, 80131 Naples, ItalyDepartment of Pulmonary Oncology, AORN dei Colli Monaldi, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, 81100 Naples, ItalyDepartment of Radiology, AORN dei Colli Monaldi, 80131 Naples, ItalyDepartment of Pulmonary Oncology, AORN dei Colli Monaldi, 80131 Naples, ItalyImmunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing, impairing our capacity to personalize and guide treatment. Therefore, this paper aims to analyze the most promising emerging predictive biomarkers that could help us in the near future to select patients more effectively.https://www.mdpi.com/2673-5261/2/2/17advanced NSCLCimmunotherapypredictive biomarkersPD-L1TMBTILS |
| spellingShingle | Luigi Della Gravara Ciro Battiloro Antonietta Letizia Rosa Cantile Vito D'Agnano Giacomo Sica Danilo Rocco Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients Journal of Molecular Pathology advanced NSCLC immunotherapy predictive biomarkers PD-L1 TMB TILS |
| title | Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients |
| title_full | Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients |
| title_fullStr | Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients |
| title_full_unstemmed | Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients |
| title_short | Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients |
| title_sort | emerging biomarkers for the selection of advanced nsclc affected immunotherapy patients |
| topic | advanced NSCLC immunotherapy predictive biomarkers PD-L1 TMB TILS |
| url | https://www.mdpi.com/2673-5261/2/2/17 |
| work_keys_str_mv | AT luigidellagravara emergingbiomarkersfortheselectionofadvancednsclcaffectedimmunotherapypatients AT cirobattiloro emergingbiomarkersfortheselectionofadvancednsclcaffectedimmunotherapypatients AT antoniettaletizia emergingbiomarkersfortheselectionofadvancednsclcaffectedimmunotherapypatients AT rosacantile emergingbiomarkersfortheselectionofadvancednsclcaffectedimmunotherapypatients AT vitodagnano emergingbiomarkersfortheselectionofadvancednsclcaffectedimmunotherapypatients AT giacomosica emergingbiomarkersfortheselectionofadvancednsclcaffectedimmunotherapypatients AT danilorocco emergingbiomarkersfortheselectionofadvancednsclcaffectedimmunotherapypatients |